English
On 28 July 2026, Health Canada updated the official Quality Overall Summary – Biologic Products (QOS-B) and Certified Product Information Document – Biologics (CPID-B) templates. These documents support quality submissions for biologic products and provide standardized formats for presenting manufacturing and quality information during regulatory review.
The updated templates are intended to improve the organization and consistency of Chemistry, Manufacturing and Controls (CMC) documentation submitted for biologic products throughout their lifecycle.
Standardizing Quality Information for Biologic Products
The QOS-B template may be used for:
New Drug Submissions (NDS)
Supplemental New Drug Submissions (SNDS)
Notifiable Changes
Clinical Trial Applications (CTA)
CTA Amendments
While the Canadian-specific QOS-B template is voluntary, Health Canada notes that using it may help reduce the need for additional clarification requests during regulatory review. The internationally recognized QOS format continues to be accepted.
Greater Emphasis on Manufacturing and Cell Culture Control
The updated QOS-B template covers key manufacturing and quality elements throughout biologic production, including:
Drug substance and drug product manufacturing processes
Upstream and downstream process descriptions
Master Cell Bank (MCB) and Working Cell Bank (WCB) information
Cell substrate characterization
Raw material control, including media, buffers, filters, and chromatography resins
Critical process parameters and process validation
Batch analysis and manufacturing consistency
Host cell-related impurities
Adventitious agent and viral safety evaluation
Stability studies
Container closure systems
Microbiological quality attributes
These sections reflect the continued importance of comprehensive quality documentation throughout biologic product development and commercial manufacturing.
CPID-B Supports Lifecycle Quality Management
Health Canada also updated the Certified Product Information Document – Biologics (CPID-B) template.
The CPID-B serves as a standardized summary of key manufacturing information following product approval. It includes details such as:
Cell line and expression system
Master and Working Cell Banks
Manufacturing scale
Critical process controls
Stability commitments
Shared manufacturing facilities
Expression platforms such as CHO and E. coli
The standardized format supports regulatory communication and facilitates lifecycle management of licensed biologic products.
What This Means for Biopharmaceutical Manufacturers
Although disposable cell culture consumables are not submitted as standalone regulatory documents, their performance and documentation can influence upstream manufacturing control and CMC preparation.
As regulatory expectations continue to evolve, manufacturers increasingly require:
Consistent product specifications
Lot-to-lot traceability
Sterility assurance
Material documentation
Supplier qualification
Change control management
Reliable supporting documentation helps strengthen manufacturing consistency and may reduce the need for regulatory clarification during product review.
FDCELL supplies sterile Cell Culture Flasks, Cell Factories, Erlenmeyer Shake Flasks, Media Bottles, and other cell culture consumables designed to support research, process development, and large-scale biologic manufacturing with comprehensive quality documentation and batch traceability.
Source
Health Canada
Quality Overall Summary – Biologic Products (QOS-B)
Certified Product Information Document – Biologics (CPID-B)
Updated: 28 July 2026
The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.
The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.
In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.
Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.
NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.
In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.